INNOVATIVE DRUGS IN STIMULATING LOCAL BLOOD PERFUSION

TO

ENABLE WOUND HEALING,TREATMENT OF MAJOR EYE AND AGING DISEASES

Reto Naef, PhD, MBACEO and FounderTopadur Pharma AG

Grabenstrasse 11A8952 Schlieren / ZurichSwitzerlandTel. +41 44 755 44 66

Reto.naef@topadur.com

© Topadur Pharma AG | January 2020

The Company

Founded2009 GmbH, 2015 AGLocation: Schlieren/ZurichEmployees: 17 (12 FTEs)

FINANCIALS (past)15.5 M US$ equity3.5 M US$ non-dilutive1.6 M US$ pending

CURRENT EQUITY ROUND8-12 M US$ Expected exit: 2022

NEXT MILESTONESFIH (TOP-N53)

Problem Indications & MarketsChronic non-healing wounds, excessive scar formationOcular blood flow, medical cosmetics

PDE5enzyme

inhibitioncGMP

sGCenzyme

stimulation

Topadur Drug Platform

Topadur invented LMW drugs based on two key enzymes incGMP metabolism, leading to increased blood perfusion,

stimulating angiogenesis and tissue regeneration to enable new therapies for several indications with high medical needs.

Local application of the angiogenetic drug candidates is expected to result in sustainable disease modification.

Invention & Solution

© Topadur Pharma AG | January 2020

ManagementLeadership and Board Members

150 years in total - within Pharma

LEADERSHIP TEAM BOARD MEMBERS

Dr. Guido Koch

COO

Dr. Reto Naef

CEO & President of Board

Dr. Hermann Tenor

CSO

Christina Attaalla

CFODr. Christian Ludin

Head Development,

Legal & Secretary o. B.

Pascal Brenneisen

Investor, Legal, Marketing

Prof. Dr. Günther Wess

R&D, Diabetes

Dr. Dominik Escher

Serial Founder,

Ophthalmology

© Topadur Pharma AG | January 2020

Endothelial Dysfunction -The Solution

Topadur’s unique Drug Platform - based on sGC Stimulation and PED5 Inhibition

© Topadur Pharma AG | January 2020

Key target cells

Cellular targets and funcional effects increasing cGMP signaling; Topadur’s dual MoA drugs

Cell type Functional effect of cGMP

stimulation

Vascular smooth muscle Blood perfusion

Endothelial cells Angiogenesis

Retinal ganglion cells Neuroprotection

Hair cells Preservation

Fibroblasts Anti-fibrotic

Intestinal epithelial cells Prevention of colorectal tumors

Head and neck SCC Growth retardation. aptoptosis

© Topadur Pharma AG | January 2020

Wound healingAngiogenesis

TOP-N53 1st priority

• Diabetic foot ulcers• Orphan ulcera• Decubitus• Major surgery

Scar preventionAnti-fibrotic

TOP-N443rd priority

• Burn wounds• Skin fibrosis• Fibrotic lung/eye

diseases

Opportunistic R&D

TOP-M119TOP-N53; TOP-V122

• Pulmonary ArterialHypertension

• Medical CosmeticsAlopecia, Skin aging

• HNSCC & colon cancerCancer stem cells

Ocular blood flowNeuroprotection

TOP-V1222nd priority

• Glaucoma• dry AMD• Diabetic

Retinopathy

Portfolio andPrioritiesR & D Portfolio

© Topadur Pharma AG | January 2020

lead finding profiling in vitro POC in vivo POC toxicology FIH Phase 1 Phase 2a/b Phase 3

preclinical clinical

Priority Projects

Opportunistic Projects

Pipeline Overview

DFU & wound healing

Scar formation, burn wounds

Normal tension glaucoma

PAH, hair growth, skin aging, Chemotherapy induced hair loss

Colorectal cancer prevention,Elimination cancer stem cells

Projects forearly Partnering

Drug Candidate - Development

© Topadur Pharma AG | January 2020

Company development strategy

Maximize value

generation

Focus on Topadur priority projects

Grow and become a global player for rare wound healing indications

2019 2021 2023 2025Exit

2022

Maximize value from Topadur’s unique

IP platform through early partnering and

out-licensing after preclinical in vivo proof of concept

Bring Topadur’s priority projects to

clinical proove of concept before out-licensing

to global partners

Become a global

player in a niche

Market after IPO

© Topadur Pharma AG | January 2020

TOP-N53: Wound Healing

TOP-M119: Alopecia

TOP-V122: Ophthalmic indications

0

1000

2000

3000

4000

5000

6000

7000

2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040

Total future Sales & Profits - 3 Main Drug Products

future sales TOP-N53+TOP-M119+TOP-V122+TOP-T5

future profits main products TOP-N53+TOP-M119+TOP-V122+TOP-T5

Mio USD

Expected longer-term Future Sales & Profits -Outlook for Valuation

Expected Sales & Profits - 3 most advanced Drug Products

© Topadur Pharma AG | January 2020

OverviewFinancials

Financial Forecast

© Topadur Pharma AG | January 2020

1. TOP-N53 2. TOP-V122, TOP-T5DIABETES FOOT GLAUCOMA, OPHTHAPAH PAH (back-up)

3. TOP-M119 4. TOP-N44ALOPECIA BURN WOUNDSHEARING LOSS

“HEALTH IS THE MOST IMPORTANT THING“

- Winner - IMD Startup 2016

- Top 100 - Swiss Startups 2017

- Winner - Swiss Innovation Challenge 2017

- Winner - Venture Leaders China 2018

- Winner - SEF High-Tech Award 2018

- Top 100 - Swiss Startups 2018

- Winners - Pitching Battle CEO day 2015

- Finalist - Swiss Innovation Challenge 2015

- Winner - Venture Leaders Life Science 2016

- Top 100 - Swiss Startups 2016

- CTI - Label Company 2016

- Top 100 - Swiss Startups 2019

- IPIEC Global Top 10 (2100 start-ups) 2019

- Winner 2019 WIPO

AWARDS: